Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Proteogenomic Screens Identify Plasma Cell Specific Vulnerabilities to Halt Oncogenic Transcription in Multiple Myeloma

Arnold Bolomsky, Smriti Kanangat, Michele Ceribelli, Kristina Rinaldi, Lin Zhang, Elizabeth Hill, Jagan R. Muppidi, Craig J. Thomas, Ryan M. Young

Blood (2024) 144 (Supplement 1): 763.

https://doi.org/10.1182/blood-2024-208485

Published: 2024

Journal Articles

Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis

Blood (2024) 144 (Supplement 1): 1722.

https://doi.org/10.1182/blood-2024-197987

Published: 2024

Journal Articles

Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease

Blood (2024) 144 (Supplement 1): 750.

https://doi.org/10.1182/blood-2024-197956

Published: 2024

Journal Articles

Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2023) 142 (Supplement 1): 434.

https://doi.org/10.1182/blood-2023-180173

Published: 2023

Journal Articles

Kme-0584, a Highly Potent IRAK1/IRAK4/panFLT3 Inhibitor, Is a Promising Clinical Candidate for Hypomethylating Agent Plus Venetoclax Resistant AML/MDS Patients

Jan S. Rosenbaum, Amal S. Kolt, Scott B. Hoyt, Gregory M. Hayes, Brandi L. Soldo, Craig J. Thomas, Daniel T. Starczynowski

Blood (2023) 142 (Supplement 1): 4152.

https://doi.org/10.1182/blood-2023-189899

Published: 2023

Journal Articles

Synthetic Lethal Interactions with IRAK4 Inhibition in Myeloid Malignancies

Eric J Vick, Josh Bennett, Ashley E. Cochran, Kathleen Hueneman, Lyndsey C. Bolanos, Xiaohu Zhang, Crystal McKnight, Michele Ceribelli, Carleen Klumpp-Thomas, Kwangmin Choi, Kenneth Greis, Craig J. Thomas, Daniel T. Starczynowski

Blood (2023) 142 (Supplement 1): 45.

https://doi.org/10.1182/blood-2023-177797

Published: 2023

Journal Articles

Molecular Mechanism of Action of Glucocorticoids in Lymphoma Therapy

Blood (2023) 142 (Supplement 1): 2986.

https://doi.org/10.1182/blood-2023-174325

Published: 2023

Journal Articles

Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML

Joshua Bennett, Chiharu Ishikawa, Puneet Agarwal, Jennifer Yeung, Avery Sampson, Emma Uible, Eric Vick, Lyndsey C. Bolanos, Kathleen Hueneman, Mark Wunderlich, Amal Kolt, Kwangmin Choi, Andrew Volk, Kenneth D. Greis, Jan Rosenbaum, Scott B. Hoyt, Craig J. Thomas, Daniel T. Starczynowski

Blood (2023) 142 (11): 989–1007.

https://doi.org/10.1182/blood.2022018718

Published: 2023

Includes: Supplemental data

Journal Articles

IRAK1 Contributes to IRAK4 Inhibitor Resistance Via Non-Canonical Signaling Mechanisms in MDS/AML

Josh Bennett, Jennifer Yeung, Avery Sampson, Kathleen Hueneman, Mark Wunderlich, Kwangmin Choi, Andrew Volk, Scott B. Hoyt, Craig J. Thomas, Daniel T. Starczynowski

Blood (2022) 140 (Supplement 1): 2240–2241.

https://doi.org/10.1182/blood-2022-167526

Published: 2022

Journal Articles

Inhibition of Both IRAK1 and IRAK4 Is Required for Complete Suppression of NF-Kb Signaling across Multiple Receptor-Mediated Pathways in MDS and AML

Jan S Rosenbaum, Scott B. Hoyt, Amal S. Kolt, Daniel A Luedtke, Craig J. Thomas, Daniel T. Starczynowski

Blood (2022) 140 (Supplement 1): 5949–5950.

https://doi.org/10.1182/blood-2022-167783

Published: 2022

Journal Articles

Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances Anne Tosto, Amynah Pradhan, Anna Marie Juanitez, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson

Blood (2022) 140 (Supplement 1): 6602–6603.

https://doi.org/10.1182/blood-2022-167950

Published: 2022

Journal Articles

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances Anne Tosto, Rafic J. Farah, Seung Tae Lee, Amynah Pradhan, Anna Marie Juanitez, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson

Blood (2022) 140 (Supplement 1): 2289–2291.

https://doi.org/10.1182/blood-2022-167887

Published: 2022

Journal Articles

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, Milos D. Miljkovic, James D. Phelan, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Anna Marie Juanitez, Amynah Pradhan, Amy Hillsman, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson

Blood (2021) 138 (Supplement 1): 3537.

https://doi.org/10.1182/blood-2021-147032

Published: 2021

Journal Articles

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, James D. Phelan, PhD, Jagan R. Muppidi, MD PhD, Craig J. Thomas, PhD, Michele Ceribelli, PhD, Frances Anne Tosto, MS, Craig A. Portell, MD, Rafic J. Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141447

Published: 2020

Journal Articles

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Blood (2019) 134 (Supplement_1): 3934.

https://doi.org/10.1182/blood-2019-124178

Published: 2019

Journal Articles

A Druggable TCF4 and BRD4 Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm

Michele Ceribelli, PhD, Priscilla N Kelly, Stefania Pittaluga, MD PhD, Craig J Thomas, PhD, Boris Reizis, PhD, Louis M. Staudt, MD PhD

Blood (2016) 128 (22): 1513.

https://doi.org/10.1182/blood.V128.22.1513.1513

Published: 2016

Journal Articles

Molecular Analysis and In Vivo Efficacy Studies on a Novel Chemical-Series of FLT3 Inhibitors in Human FLT3-ITD AML

Katelyn Melgar, MacKenzie Walker, Jiang-kang Jiang, Kelli Wison, Kwangmin Choi, PhD, James C. Mulloy, PhD, Craig J Thomas, PhD, Daniel T Starczynowski, PhD

Blood (2016) 128 (22): 36.

https://doi.org/10.1182/blood.V128.22.36.36

Published: 2016

Journal Articles

Novel Small Molecule FLT3 Inhibitors for the Treatment of FLT3-ITD AML

Katelyn Melgar, MacKenzie Walker, Jian-kang Jiang, PhD, Kelli Wilson, PhD, James C. Mulloy, PhD, Craig J Thomas, PhD, Daniel T Starczynowski, PhD

Blood (2015) 126 (23): 3690.

https://doi.org/10.1182/blood.V126.23.3690.3690

Published: 2015

Journal Articles

Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK–mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma

Scott R. P. McDonnell, Steven R. Hwang, Delphine Rolland, Carlos Murga-Zamalloa, Venkatesha Basrur, Kevin P. Conlon, Damian Fermin, Thomas Wolfe, Alexander Raskind, Chunhai Ruan, Jian-Kang Jiang, Craig J. Thomas, Cory M. Hogaboam, Charles F. Burant, Kojo S. J. Elenitoba-Johnson, Megan S. Lim

Blood (2013) 122 (6): 958–968.

https://doi.org/10.1182/blood-2013-01-482026

Published: 2013

Includes: Supplemental data

Journal Articles

Phosphorylation of PKM2 by NPM-ALK Regulates a Metabolic Shift and Increased Oncogenic Potential

Scott RP McDonnell, Steven R Hwang, Venkatesha Basrur, PhD, Kevin Conlon, Damian Fermin, PhD, Carlos Murga-Zamalloa, MD, Delphine C.M. Rolland, PharmD, PhD, Craig J. Thomas, PhD, Kojo SJ Elenitoba-Johnson, MD, Megan S. Lim, MD, PhD

Blood (2012) 120 (21): 896.

https://doi.org/10.1182/blood.V120.21.896.896

Published: 2012

NARROW

Proteogenomic Screens Identify Plasma Cell Specific Vulnerabilities to Halt Oncogenic Transcription in Multiple Myeloma

Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis

Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease

Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Kme-0584, a Highly Potent IRAK1/IRAK4/panFLT3 Inhibitor, Is a Promising Clinical Candidate for Hypomethylating Agent Plus Venetoclax Resistant AML/MDS Patients

Synthetic Lethal Interactions with IRAK4 Inhibition in Myeloid Malignancies

Molecular Mechanism of Action of Glucocorticoids in Lymphoma Therapy

Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML

IRAK1 Contributes to IRAK4 Inhibitor Resistance Via Non-Canonical Signaling Mechanisms in MDS/AML

Inhibition of Both IRAK1 and IRAK4 Is Required for Complete Suppression of NF-Kb Signaling across Multiple Receptor-Mediated Pathways in MDS and AML

Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

A Druggable TCF4 and BRD4 Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm

Molecular Analysis and In Vivo Efficacy Studies on a Novel Chemical-Series of FLT3 Inhibitors in Human FLT3-ITD AML

Novel Small Molecule FLT3 Inhibitors for the Treatment of FLT3-ITD AML

Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK–mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma

Phosphorylation of PKM2 by NPM-ALK Regulates a Metabolic Shift and Increased Oncogenic Potential

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only